Literature DB >> 12756208

Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.

Anna Westlind-Johnsson1, Sarah Malmebo, Anna Johansson, Charlotta Otter, Tommy B Andersson, Inger Johansson, Robert J Edwards, Alan R Boobis, Magnus Ingelman-Sundberg.   

Abstract

To study mechanisms behind the interindividual variability in CYP3A expression and the relative contribution of the different CYP3A enzymes to the overall CYP3A activity, we have analyzed CYP3A4, CYP3A5, CYP3A43, and PXR mRNA and CYP3A4 and CYP3A5 protein expression, catalytic activity, and polymorphism in the CYP3A5 gene in a panel of 46 Caucasian human livers. Protein quantification was performed by Western blotting using enzyme-specific antibodies directed to the C termini of CYP3A4 or CYP3A5, and carrier protein-coupled peptides as standards. The mRNA levels were determined by quantitative real-time PCR. CYP3A activity was measured by analysis of the rate of testosterone 6beta-hydroxylation. A correlation existed between all CYP3A and PXR mRNA transcripts measured. The interindividual variability in CYP3A4 and CYP3A5 mRNA expression was higher than that of CYP3A protein and activity. The CYP3A5 protein was expressed at quantifiable levels in 5 (10.9%) of the livers. Four of those were heterozygous for the CYP3A5*1 allele and had CYP3A5 protein at a mean level of 17% of that of total CYP3A, whereas one liver sample was from a CYP3A5*3 homozygote individual having lower amounts of CYP3A5. In total, CYP3A5 only contributed 2% of the overall CYP3A protein among all samples. In conclusion, our data indicate that CYP3A4, CYP3A5, CYP3A43, and PXR hepatic mRNA expression correlate, indicating common regulatory features, and that the contribution of CYP3A5 to hepatic drug metabolism in Caucasians is insignificant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12756208     DOI: 10.1124/dmd.31.6.755

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  46 in total

1.  Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.

Authors:  Landry K Kamdem; Ingolf Meineke; Ina Koch; Ulrich M Zanger; Jürgen Brockmöller; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-01       Impact factor: 3.000

2.  Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics.

Authors:  Margit Fröhlich; Michael M Hoffmann; Jürgen Burhenne; Gerd Mikus; Johanna Weiss; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

3.  Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia.

Authors:  Irena Loryan; Marja Lindqvist; Inger Johansson; Masahiro Hiratsuka; Ilse van der Heiden; Ron H N van Schaik; Jan Jakobsson; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2011-10-18       Impact factor: 2.953

4.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

Review 5.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 6.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Authors:  Magnus Ingelman-Sundberg; Cristina Rodriguez-Antona
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

7.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

8.  A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.

Authors:  Su-Jun Lee; Ilse P van der Heiden; Joyce A Goldstein; Ron H N van Schaik
Journal:  Drug Metab Dispos       Date:  2006-10-11       Impact factor: 3.922

9.  Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism.

Authors:  L Oleson; L L von Moltke; D J Greenblatt; M H Court
Journal:  Xenobiotica       Date:  2010-02       Impact factor: 1.908

10.  Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling.

Authors:  Sven van Eijl; Zheying Zhu; John Cupitt; Magdalena Gierula; Christine Götz; Ellen Fritsche; Robert J Edwards
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.